|
RU2441869C2
(ru)
*
|
2005-12-21 |
2012-02-10 |
Эбботт Лэборетриз |
Противовирусные соединения
|
|
ES2395386T3
(es)
|
2005-12-21 |
2013-02-12 |
Abbott Laboratories |
Compuestos antivirales
|
|
CN101558067B
(zh)
*
|
2006-08-23 |
2014-05-28 |
库多斯药物有限公司 |
作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物
|
|
AU2007287430B2
(en)
|
2006-08-23 |
2011-07-21 |
Kudos Pharmaceuticals Limited |
2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
|
|
CA2672737A1
(en)
|
2006-12-20 |
2008-11-06 |
Abbott Laboratories |
Anti-viral compounds
|
|
WO2009039140A1
(en)
*
|
2007-09-17 |
2009-03-26 |
Smithkline Beecham Corporation |
Pyridopyrimidine derivatives as pi3 kinase inhibitors
|
|
JP2011500657A
(ja)
*
|
2007-10-15 |
2011-01-06 |
アストラゼネカ アクチボラグ |
組合せ０５９
|
|
EP2225226B1
(en)
|
2007-12-26 |
2016-08-17 |
Critical Outcome Technologies, Inc. |
Compounds and their use in a method for treatment of cancer
|
|
JP2011512395A
(ja)
*
|
2008-02-21 |
2011-04-21 |
アストラゼネカ アクチボラグ |
組合せ療法２３８
|
|
BRPI0914912A2
(pt)
*
|
2008-06-20 |
2017-06-20 |
Astrazeneca Ab |
processo para a preparação de um composto, e de um inibidor de mtor quinase, sal de fumarato, composição farmacêutica, uso de um sal de fumarato, e, métodos para produzir um efeito inibitório mtor, e para produzir um efeito anti-câncer em um animal de sangue quente
|
|
EP3023426A1
(en)
|
2008-07-17 |
2016-05-25 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
|
UA101676C2
(uk)
*
|
2008-07-31 |
2013-04-25 |
Дженентек, Инк. |
Піримідинові сполуки, композиції і способи застосування
|
|
BRPI0921802A8
(pt)
*
|
2008-10-31 |
2018-03-13 |
Novartis Ag |
uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo.
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
BR112012011823A2
(pt)
|
2009-11-18 |
2019-09-24 |
Novartis Ag |
métodos e composições para tratar tumores sólidos e outras malignidades
|
|
WO2011067348A2
(en)
|
2009-12-03 |
2011-06-09 |
Novartis Ag |
Mek inhibitor salts and solvates thereof
|
|
WO2011067356A2
(en)
|
2009-12-03 |
2011-06-09 |
Novartis Ag |
Polymorphs of a mek inhibitor
|
|
PH12012501581A1
(en)
|
2010-02-03 |
2012-10-22 |
Signal Pharm Llc |
Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
|
|
EP2539337A1
(en)
*
|
2010-02-22 |
2013-01-02 |
F. Hoffmann-La Roche AG |
Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
|
|
BR112012024585A2
(pt)
|
2010-03-30 |
2016-05-31 |
Novartis Ag |
inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas
|
|
US8987272B2
(en)
|
2010-04-01 |
2015-03-24 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of HIV
|
|
AU2011240735B2
(en)
|
2010-04-13 |
2015-01-29 |
Novartis Ag |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer
|
|
US20130096149A1
(en)
|
2010-06-25 |
2013-04-18 |
Novartis Ag |
Heteroaryl compounds and compositions as protein kinase inhibitors
|
|
WO2012099581A1
(en)
|
2011-01-19 |
2012-07-26 |
Takeda Pharmaceutical Company Limited |
Dihydrofuropyrimidine compounds
|
|
HK1199068A1
(en)
|
2011-08-03 |
2015-06-19 |
西格诺药品有限公司 |
Identification of gene expression profile as a predictive biomarker for lkb1 status
|
|
CN102911172A
(zh)
*
|
2011-08-04 |
2013-02-06 |
上海恒瑞医药有限公司 |
杂芳基并嘧啶类衍生物、其制备方法和用途
|
|
CN103374021B
(zh)
*
|
2012-04-21 |
2015-10-28 |
通化济达医药有限公司 |
含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
|
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
|
JP6290917B2
(ja)
|
2012-11-29 |
2018-03-07 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
アザキナゾリンカルボキサミド誘導体
|
|
JP6382945B2
(ja)
|
2013-04-17 |
2018-08-29 |
シグナル ファーマシューティカルズ，エルエルシー |
ジヒドロピラジノ−ピラジンによる癌治療
|
|
MX368286B
(es)
|
2013-04-17 |
2019-09-27 |
Signal Pharm Llc |
Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
|
|
BR112015026257B1
(pt)
|
2013-04-17 |
2022-12-20 |
Signal Pharmaceuticals, Llc |
Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
|
|
HK1221150A1
(zh)
|
2013-04-17 |
2017-05-26 |
西格诺药品有限公司 |
用二氢吡嗪并-吡嗪类对癌症的治疗
|
|
MX393164B
(es)
|
2013-04-17 |
2025-03-21 |
Signal Pharm Llc |
Formulaciones farmacéuticas, proceso, formas sólidas y métodos de uso relacionados con 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-ii)piridin-3-ii)-3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona.
|
|
CN105339008A
(zh)
|
2013-04-17 |
2016-02-17 |
西格诺药品有限公司 |
用于治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯酰胺的组合疗法
|
|
EP2986321A1
(en)
|
2013-04-17 |
2016-02-24 |
Signal Pharmaceuticals, LLC |
Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
|
|
NZ629486A
(en)
|
2013-05-29 |
2017-11-24 |
Signal Pharm Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
|
|
EP3131551A4
(en)
|
2014-04-16 |
2017-09-20 |
Signal Pharmaceuticals, LLC |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
|
TWI656121B
(zh)
*
|
2014-08-04 |
2019-04-11 |
德商拜耳製藥公司 |
２－（嗎啉－４－基）－１，７－萘啶
|
|
CN106008559B
(zh)
*
|
2015-03-25 |
2020-10-16 |
中国科学院上海药物研究所 |
取代吡啶并嘧啶类化合物的合成工艺
|
|
WO2018144791A1
(en)
*
|
2017-02-03 |
2018-08-09 |
Millennium Pharmaceuticals, Inc. |
Combination of vps34 inhibitors and mtor inhibitors
|
|
IL271491B2
(en)
|
2017-06-22 |
2023-09-01 |
Celgene Corp |
Treatment of carcinoma of the liver characterized by hepatitis b virus infection
|
|
CN111315750B
(zh)
|
2017-11-06 |
2022-12-23 |
南京明德新药研发有限公司 |
作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
|
|
WO2021133509A1
(en)
*
|
2019-12-27 |
2021-07-01 |
Angex Pharmaceutical, Inc. |
Heterocyclic compounds as mtor inhibitors
|
|
KR20220140515A
(ko)
|
2020-01-13 |
2022-10-18 |
버지 애널리틱스, 인크. |
치환된 피라졸로-피리미딘 및 그의 용도
|
|
US20240208964A1
(en)
*
|
2020-06-03 |
2024-06-27 |
Pyridopyrimidines And Methods Of Their Use |
Pyridopyrimidines and methods of their use
|
|
US20230357233A1
(en)
*
|
2020-08-26 |
2023-11-09 |
InventisBio Co., Ltd. |
Heteroaryl compounds, preparation methods and uses thereof
|
|
CN117088898B
(zh)
*
|
2022-05-13 |
2026-02-06 |
中国药科大学 |
稠环嘧啶类化合物及其制备方法、药物组合物和应用
|
|
WO2024057013A1
(en)
*
|
2022-09-12 |
2024-03-21 |
Exscientia Ai Limited |
Nlrp3 modulators
|